Intravenous (IV) Compounding Automation Market Report 2026

The intravenous (IV) compounding automation market size has grown rapidly in recent years. It will grow from $2.19 billion in 2025 to $2.45 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increasing adoption of robotic compounding systems, growing demand for chemotherapy automation, rising focus on medication safety, expansion of hospital and pharmacy automation, and increasing awareness about workflow efficiency.

The intravenous (IV) compounding automation market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing investment in AI-enabled compounding solutions, growing implementation of automated IV workstations, rising integration of software with hospital information systems, expansion of remote monitoring and predictive maintenance, and increasing development of modular and customizable compounding systems. Major trends in the forecast period include innovation in AI and machine learning for compounding, advancement in robotic and automated devices, development of smart pump and monitoring technologies, innovation in sterile compounding isolators and safety cabinets, and advancement in compact and space-saving automation solutions.

The increasing demand for pharmaceutical products is expected to drive the growth of the intravenous (IV) compounding automation market in the coming years. A pharmaceutical product is a substance or combination of substances developed for the diagnosis, treatment, prevention, or management of diseases and medical conditions in humans or animals. IV compounding automation supports pharmaceutical products by enabling accurate, safe, and efficient preparation of complex intravenous medications, ensuring precise dosing, minimizing contamination risks, and helping healthcare providers meet rising demand for high-quality therapies. For example, in November 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association, total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, increasing from €363.3 billion ($393,857 million) in 2022. As a result, the growing demand for pharmaceutical products is contributing to the expansion of the intravenous compounding automation market.

The growing adoption of personalized medicine and complex infusion protocols is also expected to propel the growth of the intravenous (IV) compounding automation market going forward. Personalized medicine involves customizing medical treatments, including drug selection and dosing, based on individual patient characteristics such as genetic makeup, biomarkers, and disease profiles. The expansion of personalized medicine is driven by the rising approval and clinical use of targeted therapies that require highly individualized intravenous dosing and preparation. IV compounding automation supports this transition by enabling accurate, consistent, and safe preparation of complex, patient-specific infusion regimens while reducing human error and contamination risks. For instance, in November 2025, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 18 new personalized medicines in 2024, representing more than 25% of all new drug approvals, following 20 approvals in 2023, many of which require individualized IV preparation. Therefore, the expanding use of personalized medicine and complex infusion protocols is driving growth in the intravenous compounding automation market.

The rising number of pharmaceutical clinical trials is expected to further support the growth of the intravenous (IV) compounding automation market in the coming years. Pharmaceutical clinical trials are structured research studies conducted to assess the safety, effectiveness, and optimal dosing of new drugs or therapies in human participants. The increase in pharmaceutical clinical trials is driven by the growing need for innovative treatments to address complex and emerging health conditions. IV compounding automation supports clinical trial activities by ensuring precise, consistent, and safe preparation of investigational medications, improving dosing accuracy, operational efficiency, and regulatory compliance throughout the trial process. For example, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based industry body, the number of pharmaceutical industry trials initiated in the UK rose for the second consecutive year, increasing from 411 in 2022 to 426 in 2023. Consequently, the rising number of pharmaceutical clinical trials is contributing to the growth of the IV compounding automation market.

Major companies operating in the intravenous (iv) compounding automation market are Becton Dickinson and Company, Baxter International Inc., Grifols S.A., ICU Medical Inc., Omnicell Inc., Fresenius Kabi AG, Equashield Medical Ltd., Health Robotics S.r.l., Loccioni Group, Loccioni Group, OPTIMA pharma GmbH, Medimix Systems AG, ARxIUM Inc., General Healthy Co. Ltd., PharmaScope Onco Automation B.V., Comecer SpA, Syntegon Technology GmbH, Parata Pharmacy Automation, B. Braun SE, Aesynt Incorporated, Shenzhen Broadcare Robots Co. Ltd.

North America was the largest region in the intravenous (IV) compounding automation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (iv) compounding automation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous (iv) compounding automation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the intravenous compounding automation market by increasing costs of imported robotic arms, sensors, control electronics, sterile enclosures, and automation software components. hospitals and compounding pharmacies in north america and europe are most affected due to reliance on imported robotic systems, while asia-pacific faces pricing pressures on automation equipment exports. these tariffs are increasing capital expenditure and slowing adoption among mid-sized facilities. however, they are also driving localized system integration, regional assembly, and domestic software innovation.

Intravenous (IV) compounding automation involves the use of advanced robotic systems and software to prepare intravenous medications with a high level of accuracy and efficiency. It ensures precise dosing, minimizes human error, and preserves sterility throughout the compounding process. This approach streamlines medication preparation workflows in healthcare environments while improving patient safety and operational efficiency.

The primary product types of IV compounding automation include robotic compounding systems, automated compounding devices, software platforms, and others. Robotic systems automate preparation of IV medications with high accuracy, reducing contamination and error risk. Supporting services include installation, maintenance, training, consulting, integration, validation, software updates, calibration, and remote monitoring. Applications include chemotherapy, parenteral nutrition, antibiotics, and more, serving hospitals, compounding pharmacies, oncology centers, and others.

The intravenous (IV) compounding automation market includes revenues earned by entities by providing services such as installation, maintenance, training, consulting, support, system integration, validation, software updates, calibration, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The intravenous (IV) compounding automation market consists of sales of robotic compounding systems, automated IV workstations, IV workflow software, barcode scanners, safety cabinets, sterile compounding isolators, automated filling machines, smart pumps, sensors, and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.